Logotype for THG PLC

THG (THG) H2 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for THG PLC

H2 2025 earnings summary

26 Mar, 2026

Executive summary

  • Delivered strong FY2025 results, exceeding guidance and market consensus with adjusted EBITDA of £76.6m and operating profit swinging to £8.1m from a prior year loss of £147.9m.

  • Achieved full-year revenue growth of 2.3% after a strategic transition, with strong H2 and Q4 momentum; completed demerger of Ingenuity, now focused on Beauty and Nutrition.

  • Significant deleveraging with net debt reduced by £71m to £233m, supported by the sale of Claremont, equity raise, and debt facilities extended to 2029.

  • THG Beauty delivered its strongest Q4 growth since 2021, while THG Nutrition saw growth in all quarters, driven by online recovery and retail expansion.

Financial highlights

  • Group revenue: £1,717.0m (+2.3% CCY); THG Beauty: £1,107.9m (+0.2% CCY); THG Nutrition: £609.1m (+6.4% CCY).

  • Adjusted EBITDA reached £76.6m for FY2025; margin 4.5% (down 30bps YoY); gross margin: 40.7% (down 80bps YoY).

  • Nutrition segment delivered four consecutive quarters of growth; Myprotein achieved nearly 10% revenue growth in H2.

  • Free cash flow was negative £51.8m, impacted by working capital outflow and strategic investments; CapEx held steady at £21.1m.

  • Activewear category delivered over £50m in revenue for 2025 and now represents 12% of online sales.

Outlook and guidance

  • Guiding for mid-single-digit group revenue growth and gross profit margin improvements in 2026; FY2026 revenue and adjusted EBITDA expectations reaffirmed.

  • Free cash flow generation of £25m–£50m targeted; net debt expected to reduce to £110m–£130m before any strategic asset disposals, supported by VAT repayments and cash generation.

  • Expecting meaningful EBITDA progression from sales growth, margin improvement, and OpEx savings, including AI-driven efficiencies.

  • Anticipate significant margin improvements in nutrition from VAT treatment and falling whey prices, with benefits expected to materialize over the next 12–18 months.

  • Guidance assumes no material escalation in geopolitical disruption; revenue exposure to affected Middle East regions was <1.5% in FY2025.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more